l ‐Cysteine Alleviates Peritoneal Fibrosis by Repressing PKM2 in Peritoneal Mesothelial Cells
The FASEB Journal · 2025
DOI: 10.1096/fj.202500229r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Xiaokun Ma und 14 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Division, Department of Medicine, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Peritoneal Fibrosis, Pyruvate Kinase, Peritoneum, Thyroid Hormones. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: MOST | National Natural Science Foundation of China (NSFC), National Natural Science Foundation of Guangdong, "Three big" Construction of Large Science Program of Sun Yat-Sen University.
Abstract (Originalsprache)
Peritoneal fibrosis is one of the main causes of peritoneal dysfunction and withdrawal of patients from peritoneal dialysis (PD). Our previous study has shown that high‐glucose dialysis solution promotes glycolysis in peritoneal mesothelial cells, leading to mesothelial‐to‐mesenchymal transition (MMT) and peritoneal fibrosis. However, the molecular mechanisms remain unclear. Using single‐cell RNA sequencing (scRNA‐seq) analysis of cells from the effluent of patients undergoing PD from our previous study, we found that pyruvate kinase isozymes M2 (PKM2), a key rate‐limiting enzyme of glucose metabolism, was significantly upregulated in the mesothelial cells of patients with long‐term peritoneal dialysis (LPD). Using co‐immunoprecipitation, chromatin immunoprecipitation assay, and gene silencing techniques, we revealed that PKM2 promotes the expression of transcription factor SNAI2 by acetylating histone H3K9 (H3K9ac), thereby promoting the occurrence of MMT and hence peritoneal fibrosis. l ‐cysteine, a known PKM2 inhibitor, blocked these responses and prevented PD‐induced peritoneal fibrosis. These results could provide a novel therapeutic strategy for treating peritoneal fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nephrology Division, Department of Medicine, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
- Oncology Division, Department of Medicine, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
- Department of Transplantation, Mayo Clinic, Jacksonville, Florida, USA.
- Department of Urology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
- Nephrology Division, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
ORCID-Profile: Yin Li, Yuxiang Sun, Hui Peng
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
- National Natural Science Foundation of Guangdong
- "Three big" Construction of Large Science Program of Sun Yat-Sen University
- Basic and Applied Basic Research Foundation of Guangzhou
- China Chronic Kidney Disease Management Innovation Program
- Guangdong Basic and Applied Basic Research Fund Enterprise Joint Fund
- National Natural Science Foundation of China
Zitieren
APA
Ma, X., Li, Y., Huang, Y., Sun, Y., Li, Y., Sha, Z., Lin, H., Shang, H., Wei, D., Wu, P., Hu, C., Li, C., Hu, Z., Ye, Z., & Peng, H. (2025). l ‐Cysteine Alleviates Peritoneal Fibrosis by Repressing PKM2 in Peritoneal Mesothelial Cells. The FASEB Journal. https://doi.org/10.1096/fj.202500229r
Vancouver
Ma X, Li Y, Huang Y, Sun Y, Li Y, Sha Z, et al. l ‐Cysteine Alleviates Peritoneal Fibrosis by Repressing PKM2 in Peritoneal Mesothelial Cells. The FASEB Journal. 2025. doi:10.1096/fj.202500229r
BibTeX
@article{Ma2025,
author = {Ma, Xiaokun and Li, Yin and Huang, Yuebo and Sun, Yuxiang and Li, Yongjie and Sha, Zixin and Lin, Hongchun and Shang, Hongli and Wei, Dandan and Wu, Peizhi and Hu, Cheng and Li, Canming and Hu, Zhaoyong and Ye, Zengchun and Peng, Hui},
title = {l ‐Cysteine Alleviates Peritoneal Fibrosis by Repressing PKM2 in Peritoneal Mesothelial Cells},
journal = {The FASEB Journal},
year = {2025},
doi = {10.1096/fj.202500229r}
}
EUVIMED